Low Levels of IgM Antibodies against an Advanced Glycation Endproduct-Modified Apolipoprotein B100 Peptide Predict Cardiovascular Events in Nondiabetic Subjects.

Daniel Engelbertsen, Jenifer Vallejo, Tâm Dan Quách, Gunilla Nordin Fredrikson, Ragnar Alm, Bo Hedblad, Harry Björkbacka, Thomas L Rothstein, Jan Nilsson, Eva Bengtsson

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Low Levels of IgM Antibodies against an Advanced Glycation Endproduct-Modified Apolipoprotein B100 Peptide Predict Cardiovascular Events in Nondiabetic Subjects.'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology